Careers  |  Sign In  |  Register

Novo Nordisk Drug Shows Promise for Weight Loss in Diabetes Patients

Vitctoza, a diabetes drug for weight loss therapy, showed promise in a late-stage clinical trial, an article published by Reuters reports. A 56-week study of 846 overweight and obese type 2 diabetes patients revealed that more weight was lost by individuals who received a 3 milligram injection of Victoza, compared to those who were given a placebo. 50 percent of patients being administered Victoza lost at least 5 percent of their body weight, while another 22 percent shed 10 percent or more. The drug will seek FDA approval in September, where a panel discussion will be held before a final decision is made.

Read the article published by Reuters.